SUBSCRIBE
SUBSCRIBE

Eisai Inc.

NEWS
Eisai to Present Latest Data on Perampanel and Rufinamide at 71st American Epilepsy Society Annual Meeting
Inovelon will be presented at the 71st AES Annual Meeting to be held from December 1 to 5, 2017 in Washington D.C. in the United States.
November 27, 2017
 · 
2 min read
Load More
  • 2025 BPTW Badge - RBG.png
JOBS
IN THE PRESS
Drug Development
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer’s Disease to Better Serve Patients
March 5, 2024
 · 
3 min read
EISAI TO PRESENT DATA ON LECANEMAB and OTHER ALZHEIMER’S DISEASE RESEARCH AT THE AD/PD™ 2024 ANNUAL MEETING
February 28, 2024
 · 
11 min read
Biotech Beach
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
February 22, 2024
 · 
6 min read
Pharm Country
Eisai Aims to Advance Genitourinary Cancer Treatment with New Research at ASCO GU 2024
January 18, 2024
 · 
24 min read
Pharm Country
Eisai Furthers Oncology Research in Gastrointestinal Cancer Treatment with New Data at ASCO GI 2024
January 16, 2024
 · 
25 min read
Angle PLC - Contract announcement with Eisai Inc.
January 2, 2024
 · 
3 min read
Drug Development
EpiVax Licenses ISPRI Toolkit to Eisai for Preclinical in silico Immunogenicity Screening
December 20, 2023
 · 
2 min read
Drug Development
Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
December 8, 2023
 · 
73 min read
Business
Update relating to LEQEMBI® from Eisai’s investor presentation of their quarterly report published today
November 7, 2023
 · 
6 min read
Genetown
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results & Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The CTAD Conference
October 25, 2023
 · 
27 min read
Load More